9 α,11 β-prostaglandin F 2 in pregnancies at high risk for hypertensive disorders of pregnancy, and the effect of acetylsalicylic acid

Abstract

Our purpose was to determine urinary 9 α,11 β-prostaglandin F 2, the primary metabolite of prostaglandin D 2, in pregnancies at high risk for hypertensive disorders and the effect of acetylsalicylic acid on 9 α,11 β-prostaglandin F 2. Ninety high risk women were randomised to acetylsalicylic acid and placebo groups at 12–14 weeks of gestation, with 43 women in both groups followed up succesfully. 9 α,11 β-prostaglandin F 2 was determined at baseline, at 24–26, and at 32–34 weeks of gestation. Fifteen normotensive non-pregnant women, 17 normotensive pregnant women at 12–14, and 15 at 30–34 weeks of gestation served as controls. Urinary 9 α,11 β-prostaglandin F 2 was significantly higher in pregnant women at 12–14 weeks of gestation as compared to non-pregnant women. High risk pregnancies had higher 9 α,11 β-prostaglandin F 2 as compared to normotensive pregnancies at 12–14, and at 30–34 weeks of gestation. Urinary 9 α,11 β-prostaglandin F 2 increased throughout pregnancy unrelated to the outcome of the pregnancy or to the treatment.